GBM AGILE Trial Save

Date Added
January 21st, 2020
PRO Number
Pro00089802
Researcher
David Cachia

List of Studies

Silhouette
Keywords
Brain Tumor, Glioblastoma
Summary

Glioblastoma adaptive, global, innovative learning environment or GBM AGILE trial is to identify effective therapies and improve survival for a type of brian cancer called glioblastoma (GBM) and to match effective therapies with adult patients with newly diagnosed or recurring glioblastoma. Eligible participants will have a 50/50 chance of taking either standard therapy medications or a medication not yet approved by the FDA called regorafenib during their standard of care treatment for GBM.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
Kellej@musc.edu

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy Save

Date Added
February 19th, 2019
PRO Number
Pro00086308
Researcher
Scott Lindhorst

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Brain, Glioblastoma
Summary

This study is for men and women with glioblastoma. The purpose is to see if we can lower the chance of memory loss by adding the drug Ramipirl to the usual chemoradiation treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized, Double-Blind Phase II Trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly diagnosed Glioblastoma (GBM) Save

Date Added
January 8th, 2019
PRO Number
Pro00083430
Researcher
David Cachia

List of Studies

Silhouette
Keywords
Glioblastoma
Summary

The purpose of this study is to find out if adding a chemotherapy drug called pembrolizumab and a vaccine to standard of care treatment (temodar and radiation therapy) for glioblastoma improves survival.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
kellej@musc.edu

Change_preferences

-- OR --

Create_login